NLS Pharmaceutics (NCEL) Stock Price, News & Analysis

Company Overview

NLS Pharmaceutics (NASDAQ: NCEL) is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, with additional operations in the United States. The company focuses on the development of small-molecule therapies designed to address disorders of the circadian rhythm and sleep-wake cycle. It leverages proprietary controlled-release and receptor-targeting approaches to optimize drug exposure over a 24-hour period.

The core of NLS Pharmaceutics’ pipeline consists of novel melatonin receptor agonists aimed at treating rare and orphan sleep disorders such as non-24-hour sleep-wake disorder and idiopathic hypersomnia. Its lead candidate has advanced into mid-stage clinical trials, where the company is evaluating safety, tolerability and efficacy in patients experiencing severe disruptions in their sleep-wake patterns. Preclinical programs are also exploring additional indications in related neurophysiological and metabolic conditions.

Founded in 2015, NLS Pharmaceutics has built a research platform that integrates advanced pharmacokinetic modeling with circadian biology to enhance therapeutic outcomes. The company collaborates with academic institutions and sleep-medicine centers in North America and Europe to support patient recruitment and biomarker development. Through these partnerships, NLS Pharmaceutics aims to accelerate proof-of-concept studies and bring innovative treatments to market more efficiently.

NLS Pharmaceutics is led by an executive team with extensive experience in drug discovery, clinical development and regulatory affairs. The company’s strategy centers on addressing underserved patient populations and leveraging its circadian platform to expand into new therapeutic areas. By focusing on precise modulation of biological rhythms, NLS Pharmaceutics seeks to deliver differentiated therapies that improve quality of life for patients with chronic sleep and circadian disorders.

Key Stats

• Today's Range: $3.37 to $3.61
• 50-Day Range: $2.49 to $4.91
• 52-Week Range: $1.83 to $30.80
• Volume: 4,664 shs
• Average Volume: 65,095 shs
• Market Capitalization: $19.21 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

NLS Pharmaceutics Stock Analysis - MarketRank™

NLS Pharmaceutics scored higher than 12% of companies evaluated by MarketBeat, and ranked 805th out of 849 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

NLS Pharmaceutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

NLS Pharmaceutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

NLS Pharmaceutics has a P/B Ratio of 2.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.69% of the float of NLS Pharmaceutics has been sold short.

Short Interest Ratio / Days to Cover

NLS Pharmaceutics has a short interest ratio ("days to cover") of 0.68, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NLS Pharmaceutics has recently increased by 51.43%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NLS Pharmaceutics does not currently pay a dividend.

Dividend Growth

NLS Pharmaceutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for NCEL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of NLS Pharmaceutics in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $374,998.00 in company stock, which represents 1.9543% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, NLS Pharmaceutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $374,998.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

16.40% of the stock of NLS Pharmaceutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

NLS Pharmaceutics has minimal institutional ownership at this time.

Company Calendar

• Today: 6/24/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NCEL
• Previous Symbol: NASDAQ:NLSP
• CIK: 1783036
• Web: www.nlspharma.com
• Phone: 41-44-512-2150
• Fax: 41-41-618-8009
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.76
• Quick Ratio: 0.76

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.59 per share
• Price / Book: 2.26

Miscellaneous

• Outstanding Shares: 5,350,000
• Free Float: 4,468,000
• Market Cap: $19.21 million
• Optionable: Not Optionable
• Beta: 0.94